Bladder cancer marker shows promises in study
This article was originally published in Clinica
A screening test based on a new urinary marker for bladder cancer has been found to have a sensitivity of 100% in preliminary trials. Yale University in New Haven, Connecticut, has filed a US patent application covering a method for detecting the marker, the naturally occurring apoptosis inhibitor survivin. Survivin is over-expressed in common cancers.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.